FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1518372007> ?p ?o ?g. }

• W1518372007 endingPage "206" @default.
• W1518372007 startingPage "200" @default.
• W1518372007 abstract "Study Type – Therapy (individual cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Sorafenib is an oral receptor tyrosine kinase inhibitor that inhibits RAF serine/threonine kinases and receptor tyrosine kinases (vascular endothelial growth factor receptors 1, 2, 3 and platelet‐derived growth factor‐beta, Flt‐3 and c‐kit) that are implicated in tumourigenesis and tumour progression. Sorafenib is approved for the treatment of advanced renal cell cancer. B‐RAF mutations (V600E and K601E) may be interesting negative predictive markers in metastatic kidney cancer patients treated with Sorafenib. Larger trials are needed to validate this hypothesis and should include B‐RAF molecular analysis for better patient selection. OBJECTIVE To assess both clinical and biological efficacy and toxicity of sorafenib in patients with metastatic renal cell carcinoma (mRCC) previously treated with an anti‐angiogenic vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. METHODS Sorafenib is an orally active multikinase inhibitor approved for the treatment of mRCC. Drug‐focused translational research on tissues (i.e. B‐RAF) and plasma (VEGFR‐α, circulating endothelial cells, endothelial progenitor cells) was performed to define biological predictive and prognostic markers and their related kinetics. Patients with mRCC pretreated with an anti‐angiogenic treatment, an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–2 and adequate organ function were eligible. Patients received sorafenib 400 mg twice a day continuously in 4‐week cycles. Patients with no progressive disease at 12 weeks continued to receive sorafenib at the standard dose, whereas progressing patients received an increased dose (600 mg twice a day) with early disease restaging after 4 weeks. Patients who progressed at 600 mg twice a day went off study. Efficacy (overall tumour control) was assessed by Response Evaluation Criteria in Solid Tumors. RESULTS In all, 19 patients were entered. The baseline characteristics were as follows: ECOG PS 0–1 94.8%; median (range) age 62 (41–81) years; nephrectomy 100%; surgery for metastatic disease 26.4%; clear cell 79.1%; papillary cell 15.7%; sarcomatoid/high grade 5.2%; two or more metastatic sites 84%. Overall, 11 patients (58%) had disease control at 6 months without significant correlation between response to prior therapy and hypertension. Progression‐free survival (PFS) of 8.3 months was observed. Of six patients for whom the dose was escalated due to early progression, three benefitted with PFS of >3 months. Three (15.7%) of 19 patients had a V600E mutation and one had a K601E mutation; PFS appeared to be substantially shorter in these patients compared with 15 patients with wild‐type B‐RAF (2.5 vs 9.1 month, P < 0.05). The most common toxicity (National Cancer Institute Common Toxicity Criteria, NCIC 3.0, all patients) was grade ≥1 diarrhoea and grade 2–3 hand–foot syndrome in 11 patients. Grade 3 mucositis was observed in one patient. CONCLUSIONS Sorafenib at doses of 400–600 mg twice a day continuously results in acceptable and well tolerated salvage treatment after VEGFR tyrosine kinase inhibitor failure. In progressive patients, treatment with a higher dose could be a valid option and B‐RAF mutations may be an interesting predictive marker to be studied in a larger randomized trial." @default.
• W1518372007 created "2016-06-24" @default.
• W1518372007 creator A5004985848 @default.
• W1518372007 creator A5009508595 @default.
• W1518372007 creator A5009580959 @default.
• W1518372007 creator A5014074160 @default.
• W1518372007 creator A5050669470 @default.
• W1518372007 creator A5052612647 @default.
• W1518372007 creator A5053526286 @default.
• W1518372007 creator A5055084999 @default.
• W1518372007 creator A5060118140 @default.
• W1518372007 creator A5065833805 @default.
• W1518372007 creator A5068321284 @default.
• W1518372007 creator A5075440583 @default.
• W1518372007 date "2011-12-23" @default.
• W1518372007 modified "2023-10-17" @default.
• W1518372007 title "Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment" @default.
• W1518372007 cites W1520255941 @default.
• W1518372007 cites W1965874702 @default.
• W1518372007 cites W2004201362 @default.
• W1518372007 cites W2009664307 @default.
• W1518372007 cites W2028750359 @default.
• W1518372007 cites W2078449820 @default.
• W1518372007 cites W2102339903 @default.
• W1518372007 cites W2103304755 @default.
• W1518372007 cites W2115005218 @default.
• W1518372007 cites W2118677643 @default.
• W1518372007 cites W2123769946 @default.
• W1518372007 cites W2127786249 @default.
• W1518372007 cites W2135139265 @default.
• W1518372007 cites W2138129102 @default.
• W1518372007 cites W2140626630 @default.
• W1518372007 cites W2140765540 @default.
• W1518372007 cites W2142297664 @default.
• W1518372007 cites W2143782771 @default.
• W1518372007 cites W2149456801 @default.
• W1518372007 cites W2157262448 @default.
• W1518372007 cites W2161093387 @default.
• W1518372007 cites W2162424705 @default.
• W1518372007 cites W2164638888 @default.
• W1518372007 cites W2166788033 @default.
• W1518372007 cites W4234636179 @default.
• W1518372007 cites W4293241248 @default.
• W1518372007 doi "https://doi.org/10.1111/j.1464-410x.2011.10421.x" @default.
• W1518372007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22212284" @default.
• W1518372007 hasPublicationYear "2011" @default.
• W1518372007 type Work @default.
• W1518372007 sameAs 1518372007 @default.
• W1518372007 citedByCount "31" @default.
• W1518372007 countsByYear W15183720072012 @default.
• W1518372007 countsByYear W15183720072013 @default.
• W1518372007 countsByYear W15183720072014 @default.
• W1518372007 countsByYear W15183720072015 @default.
• W1518372007 countsByYear W15183720072016 @default.
• W1518372007 countsByYear W15183720072017 @default.
• W1518372007 countsByYear W15183720072018 @default.
• W1518372007 countsByYear W15183720072019 @default.
• W1518372007 countsByYear W15183720072020 @default.
• W1518372007 crossrefType "journal-article" @default.
• W1518372007 hasAuthorship W1518372007A5004985848 @default.
• W1518372007 hasAuthorship W1518372007A5009508595 @default.
• W1518372007 hasAuthorship W1518372007A5009580959 @default.
• W1518372007 hasAuthorship W1518372007A5014074160 @default.
• W1518372007 hasAuthorship W1518372007A5050669470 @default.
• W1518372007 hasAuthorship W1518372007A5052612647 @default.
• W1518372007 hasAuthorship W1518372007A5053526286 @default.
• W1518372007 hasAuthorship W1518372007A5055084999 @default.
• W1518372007 hasAuthorship W1518372007A5060118140 @default.
• W1518372007 hasAuthorship W1518372007A5065833805 @default.
• W1518372007 hasAuthorship W1518372007A5068321284 @default.
• W1518372007 hasAuthorship W1518372007A5075440583 @default.
• W1518372007 hasBestOaLocation W15183720071 @default.
• W1518372007 hasConcept C101544691 @default.
• W1518372007 hasConcept C121608353 @default.
• W1518372007 hasConcept C126322002 @default.
• W1518372007 hasConcept C143998085 @default.
• W1518372007 hasConcept C167734588 @default.
• W1518372007 hasConcept C170493617 @default.
• W1518372007 hasConcept C2777025900 @default.
• W1518372007 hasConcept C2777472916 @default.
• W1518372007 hasConcept C2778019345 @default.
• W1518372007 hasConcept C2778695046 @default.
• W1518372007 hasConcept C2778820342 @default.
• W1518372007 hasConcept C2779490328 @default.
• W1518372007 hasConcept C2780394083 @default.
• W1518372007 hasConcept C42362537 @default.
• W1518372007 hasConcept C502942594 @default.
• W1518372007 hasConcept C71924100 @default.
• W1518372007 hasConceptScore W1518372007C101544691 @default.
• W1518372007 hasConceptScore W1518372007C121608353 @default.
• W1518372007 hasConceptScore W1518372007C126322002 @default.
• W1518372007 hasConceptScore W1518372007C143998085 @default.
• W1518372007 hasConceptScore W1518372007C167734588 @default.
• W1518372007 hasConceptScore W1518372007C170493617 @default.
• W1518372007 hasConceptScore W1518372007C2777025900 @default.
• W1518372007 hasConceptScore W1518372007C2777472916 @default.
• W1518372007 hasConceptScore W1518372007C2778019345 @default.
• W1518372007 hasConceptScore W1518372007C2778695046 @default.

• next